The Maryland company, which has a $1.75 billion federal contract to develop and produce a coronavirus vaccine, said it needed to address the concerns of federal regulators.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register. By continuing to use this site, you are consenting to our use of cookies.